Global Biomarkers Market - 2023-2030

Global Biomarkers Market - 2023-2030

Global biomarkers market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.

Biomarkers also known as biological markers, is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. Biomarkers are used for the diagnosis health status of an individual. In medical terms, a measurable biomarker is a chemical component that reflects the presence as well as the severity of the disease.

Moreover, biomarkers are the measures used to perform a clinical assessment such as blood pressure or cholesterol level and are used to monitor and predict health states in individuals or across populations so that appropriate therapeutic intervention can be planned. Biomarkers may be used alone or in combination to assess the health or disease state of an individual. Every biological system has its own specific biomarkers. Many of these biomarkers are relatively easy to measure and form part of routine medical examinations.

Market Dynamics: Drivers

Increasing novel approaches and increasing adoption in the diagnosis of cancer

The increasing novel approaches and increasing adoption of biomarker in cancer cases is expected to drive the market over the forecast period. The biomarkers are most commonly used in the detection of cancer, especially ovarian cancer. The increasing prevalence of ovarian cancer leads to the increasing adoption of the biomarkers. For instance, according to Global Cancer Statistics, 2020, Ovarian cancer is the seventh most frequent cancer in women worldwide, accounting for around 314,000 new cases (3.4% of all new cancer cases in females) per year.

Moreover, cancer Antigen-125 (CA-125) and transvaginal imaging are commonly used to diagnose ovarian cancer. The most commonly used serum biomarker is CA-125, although it lacks the sensitivity and specificity to be utilized alone as a screening test. It is also ineffective for early diagnosis since CA-125 expression levels are too low for accurate detection.

For instance, on November 07, 2022, Akoya Biosciences, Inc. launched the PhenoCode Signature Panels for high-throughput spatial biomarker discovery and validation on the PhenoImager platforms. Each of the customizable multiplex panels includes key markers for phenotyping the tumor microenvironment (TME) and immune status. When combined with the high-speed and robust imaging of the PhenoImager platforms, a rapid, quantitative, end-to-end spatial phenotyping workflow is enabled. The workflow accelerates the development and validation of predictive signatures and prognostic biomarkers for immuno-oncology applications.

Additionally, many novel approaches are going on in the field of biomarkers. For instance, on April 19, 2021, Amgen launched the Biomarker Assist to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist, eligible patients may save on biomarker testing.

The technological advancements in biomarkers increase the adoption of biomarkers. For instance, on January 11, 2021, Biogen Inc. released a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI). The study’s primary objectives are to develop digital biomarkers to help monitor cognitive performance over time and identify early signs of MCI.

Further, the increasing prevalence of cancers, rising FDA approvals, increasing clinical trials, increasing awareness and technological advancements are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the biomarkers, high investment costs, problems such as sample storage and collection, and unfavorable reimbursement scenarios are expected to hamper the market growth during the forecast period.

Segment Analysis

The global biomarkers market is segmented based on product type, application, end-user and region.

The diagnostic biomarkers segment accounted for approximately 43.2% of the biomarkers market share

The diagnostic biomarkers segment is expected to hold the largest market share over the forecast period. The diagnostic biomarkers play a crucial role in the disease diagnosis. Diagnostic biomarkers may be used not only to identify people with a disease but also to redefine the classification of the disease. Diagnostic biomarkers identify disease subtypes and thus often play critical roles when the results of diagnostic classification can be used as prognostic biomarkers and predictive biomarkers.

For instance, on July 13, 2023, Quest Diagnostics, the leading provider of diagnostic information services, launched a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. Envision Sciences Pty Ltd. is an Australian-based clinical diagnostics company developing a pipeline of biomarker-based cancer diagnostic and prognostic tests in tissue and blood.

In addition on September 08, 2023, Ibex Medical Analytics launched Galen Breast HER2, a novel breast cancer AI-powered biomarker scoring solution developed in collaboration with AstraZeneca and Daiichi Sankyo, to support improved patient outcomes. Galen Breast HER2 allows clinicians to rapidly and accurately identify patients with HER2-low who would benefit from targeted therapies.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and biotechnology companies. The presence of major players actively adopting the biomarkers drug discovery and development of personalized medicines.

Moreover, the increasing prevalence of cancer in the region leads to the increasing adoption of biomarkers. For instance, according to the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the adoption of biomarkers for cancer.

Competitive Landscape

The major global players in the biomarkers market include Bio-Rad Laboratories Inc., Merck KGaA, QIAGEN N.V., Siemens Healthcare Private Limited, Enzo Biochem Inc., PerkinElmer Inc., BRUKER CORPORATION, Epigenomics AG, Signosis, Inc. and Thermo Fisher Scientific Inc. among others.

Key Developments
• On May 17, 2023, Chordia Therapeutics, Inc. released the beginning of field trials leveraging Fujitsu’s AI causal discovery technology to shed light on biomarkers that increase the probability of success or shorten the duration of clinical trials in the development of new cancer drugs.
• On October 25, 2022, Koneksa, a healthcare technology company developing evidence-based validated digital biomarkers, launched its clinical pipeline featuring biomarkers across neuroscience, oncology, respiratory, and other therapeutic areas. With 15 digital biomarker programs in development, the company will also be launching several upcoming clinical studies.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global biomarkers market. The pandemic led to disruptions in ongoing clinical trials, delays in the initiation of new trials, and difficulties in patient recruitment. This impacted the development and validation of biomarkers.

With the focus on understanding and combating COVID-19, there may have been a shift in research priorities and funding away from other areas, including biomarker research for different diseases. Moreover, the pandemic likely influenced the development and use of biomarkers for diagnosing COVID-19 and monitoring its severity.

Market Segmentation

By Product Type
• Diagnostic Biomarkers
• Monitoring Biomarkers
• Predictive Biomarkers
• Susceptibility/Risk Biomarkers
• Prognostic Biomarkers
• Pharmacodynamic/Response Biomarkers
• Safety Biomarkers
• Others

By Application
• Drug Discovery and Development
• Disease Diagnostics
• Disease Risk Assessment
• Personalized Medicine
• Others

By End-User
• Pharmaceutical Companies
• Biotechnology Companies
• Research Centers and Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?
• To visualize the global biomarkers market segmentation based on product type, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of biomarkers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global biomarkers market report would provide approximately 61 tables, 65 figures, and 187 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies